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Patients with chronic myeloid leukemia (CML) infrequently present in blast crisis (BC). While most BC are of myeloid origin, megakaryocytic 
BC is rare, especially at the time of CML diagnosis. We 
describe the first pediatric patient presenting with mega-
karyocytic leukemia and having BCR-ABL1 transloca-
tion as the single chromosomal abnormality. Clinical 
features were more suggestive of CML in megakaryo-
cytic blast crisis than Philadelphia chromosome posi-
tive de novo AML. The patient was treated with AML-
directed chemotherapy and imatinib mesylate followed 
by umbilical cord blood stem cell transplantation. The 
patient was in complete molecular response 16 months 
after stem cell transplantation. 
Chronic myeloid leukemia (CML) is a clonal disor-
der of pleuripotent hematopoietic stem cells character-
ized by a balanced, reciprocal translocation involving 
chromosomes 9 and 22. It has a triphasic course: chron-
ic phase (CP), accelerated phase (AP) and blast crisis 
(BC). At the time of disease progression, approximately 
65% of CML patients evolve to myeloid BC, while 
the remainder has either a lymphoid or mixed-lineage 
phenotype. Rarely, patients with CML can present di-
rectly in a blast crisis. BC with features reminiscent of 
acute megakaryocytic leukemia (AMKL) is rarely en-
countered; only five reported cases were found in the 
literature that describes AMKL as first presentation of 
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patients with chronic myeloid leukemia (cml) infrequently present in blast crisis (bc). While most bc are 
of myeloid origin, megakaryocytic bc is rare, especially at the time of cml diagnosis. We describe the 
first pediatric patient presenting with megakaryocytic leukemia and having bcr-abl1 translocation as the 
single chromosomal abnormality. clinical features were more suggestive of cml in megakaryocytic blast 
crisis than philadelphia chromosome positive de novo aml. the patient was treated with aml-directed 
chemotherapy and imatinib mesylate followed by umbilical cord blood stem cell transplantation. the 
patient was in complete molecular response 16 months after stem cell transplantation.
CML. (Table 1)1-5 All of these patients were adult. We 
believe this is the first reported case of a pediatric pa-
tient with CML who presented in megakaryocytic blast 
transformation. 
CAsE 
A 9-year-old girl presented with progressive abdominal 
distension of 8 weeks duration without any associated 
symptoms. Her medical history did not include any 
preexisting hematological or chronic disease. Physical 
examination only found splenomegaly reaching the 
iliac crest. Laboratory tests showed a hemoglobin of 
9.4 gm/dL, white blood cell count of 36×109/L and 
platelets of 582×109/L. The peripheral smear showed 
31% blast cells. Wright-Geimsa stained peripheral 
blood and bone marrow aspirate smears reviewed by a 
hematopathologist showed that there were more than 
50% medium sized blasts in the bone marrow, with a 
low nuclear:cytoplasmic ratio and multiple nucleoli. 
The cytoplasm was granular with some cytoplasmic 
blebs (Figure 1). There was a reduction in the number 
of megakaryocytes, but no increase in either basophils 
or eosinophils. Immunophenotyping of these blasts by 
FACSCalibur flowcytometer (Becton Dickinson im-
munocytometry systems, San Jose, CA, USA) showed 
more than 20% of the gated cells positive for the my-
eloid markers CD13, CD33 and CD117 and for platelet 
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markers CD41, CD42, CD61 and CD62, with partial 
positivity for myeloperoxidase. This led to a diagnosis 
of acute myeloid leukemia (AML) with megakaryocytic 
differentiation. A cytogenetic study showed karyotype 
46XY, t(9; 22)(q34; q11.2). Fluorescent is situ hybrid-
ization (FISH) for BCR-ABL translocation showed 
99% positive cells. Based on these findings a diagnosis 
of chronic myeloid leukemia in megakaryocytic blast 
crisis (CML-BC) was made. Following the initial mor-
phological and flow-cytometric diagnosis of AMKL, 
the patient was started on induction therapy accord-
ing to our AML protocol, consisting of idarubicin 12 
mg/m2  IV×3 days, cytarabine 100 mg/m2/day intrave-
nously continuous infusion×7 days and thioguanine 60 
mg/m2 orally×7 days. Cytogenetic results were received 
after completion of the first cycle of induction therapy 
at which time her diagnosis was changed to CML with 
megakaryocytic BC. Bone marrow evaluation after 
the first induction cycle revealed a decline in the bone 
marrow blasts to 7%. There was, however, little if any 
decline in the size of her spleen. As cytogenetic results 
were then available, imatinib mesylate at a dose of 340 
mg/m2 was started along with the second induction cy-
cle (idarubicin 12mg/m2 intravenously×2 days, cytara-
bine 100 mg/m2/day intravenously by continuous infu-
sion x 5 days and thioguanine 60 mg/m2 PO×5 days). 
Following this she continued on IM alone for a period 
of ten months. She achieved complete hematological 
remission (CHR) with regression of the spleen when 
she was evaluated one month following this induction 
chemotherapy. FISH for BCR-ABL1 was negative con-
firming complete cytogenetic response (CCR) as well. 
Further response evaluation also included quantita-
tive RT-PCR for BCR-ABL1, performed by amplify-
ing the generated cDNA with a BCR exon b2 forward 
probe and a reverse primer at the ABL exon a4, with 
a limit of detection at 1/10000; any result <1/10000 
underwent nested PCR. By 5 months from diagnosis 
she had achieved a major molecular response (MMR; 
>3 log reduction in BCR-ABL1 transcript) with BCR-
ABL1 detectable at <1 in 104 cells by nested PCR. 
Stem cell transplant (SCT) work-up was initiated, but 
unfortunately, as she had no matched-related donor, so 
a decision was taken to proceed with alternative donor 
SCT. She was transplanted from a one class II antigen 
mismatched unrelated umbilical cord blood (UCB) 
unit, following conditioning with busulfan, cyclophos-
phamide, antithymocyte globulin, and etoposide. She 
achieved neutrophil and platelet engraftment by day 
20 and 70 post-transplant, respectively. She had no 
major complication during transplantation, except for 
transient grade 1 graft-versus-host disease (GVHD) 
involving the skin. She received imatinib for 4 months 
post engraftment. 
At 6 weeks post SCT she had achieved undetectable 
BCR-ABL1 transcript by nested PCR. At 26 months 
from diagnosis and 16 months post-transplantation 
she remained in complete remission with undetectable 
BCR-ABL1. 
DIsCussIOn 
Progression to BC is part of the natural history for 
CML. Prior to the imatinib era, patients with CP-CML 
would develop blast crises at a median of 3 to 4 years.6 
However, this changed somewhat following the intro-
duction of interferon alfa and more so with imatinib. 
Although over two-thirds of BC in CML patients is 
of myeloid origin, megakaryocytic blast crises are fairly 
Figure 1 (a) bone marrow aspirate smear (wright-giemsa stain, original magnification ×50) showing leukemic blast cells and 
megakaryocytes. (b) metaphase images using the bCr-abl1 dual color probes demonstrating dual fusion signals (D-FiSH) compared 
to normal. 
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rare. Our patient presented with what was initially di-
agnosed as de novo AMKL and was classified as CML 
in megakaryocytic BC after cytogenetic studies were 
reported. Differentiation between de novo AMKL and 
megakaryoblastic BC of CML is difficult. In pediatric 
patients de novo AMKL generally occurs in younger 
children at a median of 22 months.7 Both de novo 
AMKL and CML-BC share the same clinical features 
and bone marrow morphology. However, the presence 
of high platelet count, splenomegaly, and basophilia may 
support the diagnosis of CML-BC.8 Our patient had 
all of these clinical features: thrombocytosis (platelet 
count 582×109/L), massive splenomegaly and periph-
eral blood basophilia (4%; absolute basophilic count 
1.46×109/L). Classically seen in CML, the Philadelphia 
chromosome (Ph) has rarely been described in de novo 
AML, including AMKL. These Ph+ de novo AML did 
not have the additional cytogenetic abnormalities that 
are seen in about 80% of CML-BC cases. Incidentally, 
as in our patient, about 20% of CML patients do not 
develop additional detectable cytogenetic lesions at 
the time of progression.9 Three of the five previously 
reported patients who presented with megakaryo-
cytic BC did not have additional karyotypic changes. 
Progression of CML signals the development of more 
aggressive disease with a significantly poorer prognosis 
when compared to CP patients, even when treated with 
imatinib. Although hematological responses are seen in 
up to 50% of patients, the 12-month survival was less 
than 30%.10 While use of conventional AML-directed 
chemotherapy has resulted in very poor outcomes 
(median survival of 3.5-15 months in responders and 
2-6 months in non-responders),11 the combination of 
conventional chemotherapy and imatinib has proven to 
be more effective. Using mitoxantrone and etoposide, 
Fruehauf et al reported HR in 67% and 100% patients 
who received IM following and concomitantly with 
chemotherapy, respectively.12 Six of the 16 patients on 
this study underwent allogeneic SCT and achieved 
a significantly better survival (median 15.7 months; 
range 4-31) as compared to 4.7 months (range 0-49) 
for chemotherapy alone. Although there was significant 
cytoreduction, chemotherapy alone did not achieve 
CHR for our patient, and only the addition of imatinib 
to the second induction cycle resulted in CHR and 
CCR. Subsequent therapy with imatinib alone resulted 
in further reduction of the BCR-ABL1+ clone achiev-
ing a MMR prior to SCT. Three of the five patients 
previously reported were also treated with imatinib, 
two in conjunction with AML-directed chemotherapy 
and one alone. Positive responses were seen only in the 
two patients who received imatinib with chemotherapy. 
It is likely that the clonal transformation and acquisi-
tion of new chromosomal abnormality favored the use 
of additional chemotherapy. Following the advent of 
tyrosine kinase inhibitors the indication or require-
ment for SCT has been questioned. Certainly in adult 
patients in CP1, SCT now holds a significantly lower 
position in treatment options for CML.13 The situation 
is more complicated for children where the long-term 
effects of imatinib are as yet unknown. For patients in 
advanced-phase CML, allogeneic SCT still provides 
significant benefit over imatinib alone and, particu-
larly in children, is considered the therapeutic option 
of choice.14 When sibling donors are unavailable, alter-
native donor transplants have also been found to be of 
benefit. Recent reports have indicated the potential use 
of UCB as a stem cell source for both adult and pediat-
ric CML patients.15-17 In one large series of both adult 
and pediatric patients, children younger than 15 years 
of age achieved a 74% 2-year EFS, which was margin-
ally better than that for adolescents/young adults and 
older adults (33% and 15%, respectively; P=.049).15 
This same study and others have reported a worse out-
come for patients transplanted in advanced phase (AP/
BC) CML. As in our patient, initial use of imatinib to 
achieve at least a reversion to CP, may result in an im-
proved outcome post SCT. 
In summary, we have described the first pediatric 
patient with CML who presented in megakaryocytic 
BC. Differentiation from the rarely encountered Ph+ 
de novo AMKL may be difficult, but these patients do 
benefit from AML-directed chemotherapy treatment 
with imatinib used concomitantly. Allogeneic SCT us-
ing any donor stem cell source may result in cure for a 
subset of these patients. 
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